Manufacturers announce positive data on aviptadil for respiratory failure related to critical COVID-19

In an open label prospective study, aviptadil was associated with an increased probability of survival and recovery from respiratory failure. Overall, 81% survived beyond 60 days vs 17% for control. Data from a phase 2b/3 trial are expected later this year.

Source:

Biospace Inc.